GlassScriptPhysician profile
Ali A Hassoun
NPI 1063404978
$262,171.18
in general payments reported to CMS, 2019-2025
31 companies · $51K in 2025
The $51K reported for 2025 was more than what 98% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $7,520 · 2021: $20K · 2022: $21K · 2023: $66K · 2024: $58K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $133K · Consulting Fee: $20K · Travel and Lodging: $15K · Food and Beverage: $6,477 · Education: $1,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $132,508.35 |
| Consulting Fee | $20,389.00 |
| Travel and Lodging | $14,795.78 |
| Food and Beverage | $6,477.04 |
| Education | $1,482.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80,066.41 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $67,353.70 | 2019-2024 | Rebyota |
| Astellas Pharma US INC | $39,626.12 | 2019-2025 | Cresemba |
| Melinta Therapeutics, LLC | $30,220.55 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Cumberland Pharmaceuticals, INC. | $13,609.49 | 2019-2025 | Vibativ, Caldolor |
| Tetraphase Pharmaceuticals, INC. | $8,506.27 | 2019-2020 | |
| Allergan, INC. | $5,548.24 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $5,413.66 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Glaxosmithkline, LLC. | $3,290.60 | 2024-2025 | Blujepa, Brexafemme |
| Shionogi INC | $2,659.57 | 2020-2023 | Fetroja |
| La Jolla Pharmaceutical Company | $2,023.44 | 2021-2025 | Zevtera, Xerava, Xacduro |
| Abbvie INC. | $1,053.22 | 2021-2025 | |
| Insmed, INC. | $1,033.73 | 2019-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $395.54 | 2019-2022 | |
| Viiv Healthcare Company | $363.48 | 2019-2025 | Dovato |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $211.06 | 2020-2025 | Egrifta, Trogarzo |
| Aimmune Therapeutics, INC. | $109.32 | 2024-2025 | Vowst |
| Octapharma USA, INC. | $94.82 | 2020 | |
| Dynavax Technologies Corporation | $86.28 | 2020-2022 | |
| Cipla USA INC. | $70.89 | 2021 | |
| Astellas Pharma Global Development | $63.69 | 2019 | |
| Janssen Scientific Affairs, LLC | $62.34 | 2022 | |
| Grifols USA, LLC | $61.61 | 2022 | |
| Mayne Pharma Commercial LLC | $61.10 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $45.90 | 2025 | Nuzyra |
| Sanofi Pasteur INC. | $44.74 | 2019-2020 | |
| Janssen Biotech, INC. | $29.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.82 | 2023 | |
| Genentech, INC. | $17.04 | 2019 | |
| Advanced Oxygen Therapy INC. | $15.02 | 2020 | |
| T2 Biosystems, INC. | $14.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Hassoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.